Search
Major Depressive Disorder Clinical Trials
A listing of 125 Major Depressive Disorder clinical trials actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
1 - 12 of 125
There are currently 125 active clinical trials seeking participants for Major Depressive Disorder research studies. The states with the highest number of trials for Major Depressive Disorder participants are California, Florida, Texas and New York.
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
Depression Clinical Trial
Recruiting
Join us in researching a potential investigational treatment for Depression. Reimbursement for study-related expenses may be available to you.
Qualifying participants:
•Are between 18-65
•Have been experiencing a major depressive episode forat least a month
Qualifying participants:
•Are between 18-65
•Have been experiencing a major depressive episode forat least a month
Conditions:
Depression
Major Depressive Disorder
Depressive Disorder
Depressive Symptoms
Depressive Disorder
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
Neuropharmacologic Imaging and Biomarker Assessments of Response to Acute and Repeated-Dosed Ketamine Infusions in Major Depressive Disorder
Recruiting
Background:
Most medications that treat depression take weeks or months to work. Researchers want to develop fast-acting treatments. One dose of ketamine has a rapid antidepressant effect. For most people, this lasts a week or less. Repeated doses of ketamine may help maintain this effect.
Objective:
Main Study: To study the effects of ketamine in treating depression.
Ketamine Metabolites Substudy: To study how ketamine effects brain chemistry.
To study how ketamine effects the brain. This... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
06/26/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Study of Neuro-Cognitive Correlates of Pediatric Anxiety Disorders
Recruiting
Study Description:
This study examines relations between neurocognitive and clinical features of pediatric anxiety disorders. The study uses neuro-cognitive tasks, functional magnetic resonance imaging (fMRI), as well as magneto- and electro-encephalography (M/EEG). Patients will be studied over one year, before and after receiving either one of two standard-of-care treatments: cognitive behavioral therapy (CBT) or fluoxetine, a serotonin reuptake inhibitor (SSRI). Healthy comparisons will be s... Read More
Gender:
ALL
Ages:
Between 8 years and 65 years
Trial Updated:
06/25/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Major Depressive Disorder, Anxiety Disorders
Efficacy and Safety Study of BHV-7000 Monotherapy in Major Depression
Recruiting
The purpose of this study is to determine the efficacy and safety of BHV-7000 in participants with Major Depressive Disorder (MDD)
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
06/24/2025
Locations: Reverie Mind, LLC, Chandler, Arizona +66 locations
Conditions: Major Depressive Disorder
Long-term Potentiation Disruption Underlying Cognitive Impairment in ECT
Recruiting
Cognitive problems, like memory loss, are common after brain injuries like trauma or stroke. These problems make daily life harder, and the investigators don't yet know the best ways to help the brain recover. Scientists think that a process in the brain called long-term potentiation (LTP) is important for memory and learning. When LTP isn't working properly, it may cause problems with thinking and memory. But studying LTP in people is hard because it happens deep inside the brain.
Our research... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
06/24/2025
Locations: Domenici Hall, Albuquerque, New Mexico
Conditions: Major Depressive Disorder, Bipolar Disorder II
Mechanism of Action Underlying Ketamine's Antidepressant Effects: The AMPA Throughput Theory in Patients With Treatment-Resistant Major Depression
Recruiting
Background:
Most drugs that treat mood disorders take a long time to work. Ketamine works within hours. A dose can last for a week or more. Certain receptors in the brain might help ketamine work. A drug that blocks these receptors might affect how it works.
Objective:
To see if the antidepressant response of ketamine is linked to AMPA receptors.
Eligibility:
Adults ages 18-70 with major depression disorder without psychotic features
Design:
Participants will be screened under protocol 01... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
06/19/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder
Recruiting
X-NOVA2 is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the clinical efficacy, safety, and tolerability of azetukalner as a monotherapy in adult participants diagnosed with Major Depressive Disorder (MDD)
Gender:
ALL
Ages:
Between 18 years and 74 years
Trial Updated:
06/18/2025
Locations: IMA Clinical Research Phoenix, Phoenix, Arizona +39 locations
Conditions: Major Depressive Disorder
Deep Brain Stimulation (DBS) Therapy for Treatment Resistant Depression
Recruiting
We propose a clinical study of medial forebrain bundle DBS as a treatment in 20 patients with treatment refractory depression (TRD). Data from the University of Bonn indicates that surgical lesions of the medical forebrain bundle can produce therapeutic benefits in patients with depressive disorders, and suggest that DBS at the same site may also reduce symptomatology in these TRD patients (Schaepfer, 2013). Depression affects up to 10% of the US population and of those at least 10-15% do not be... Read More
Gender:
ALL
Ages:
Between 22 years and 70 years
Trial Updated:
06/17/2025
Locations: UT Center of Excellence on Mood Disorders, Houston, Texas
Conditions: Major Depressive Disorder, Treatment Resistant Depression
GATE-251 or Placebo for the Reduction of Symptoms of Major Depressive Disorder
Recruiting
The goal of this clinical trial is to learn if GATE-251 works to treat depression in adults. It will also learn about the safety of GATE-251. The main questions it aims to answer are:
Does GATE-251 reduce depression scores in participants compared to participants who take a placebo (a look-alike tablet that contains no GATE-251)?
What medical problems are observed in participants who take GATE-251?
Participants will take one tablet of GATE-251 or placebo every week for 6 weeks. Participants w... Read More
Gender:
ALL
Ages:
Between 18 years and 64 years
Trial Updated:
06/17/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama +30 locations
Conditions: Major Depressive Disorder
Study of ABX-002 for the Adjunctive Treatment of Major Depressive Disorder (AMPLIFY)
Recruiting
The goal of this clinical trial is to learn if ABX-002 added to an existing antidepressant treatment will benefit depression symptoms in adults with moderate to severe major depressive disorder who have had an inadequate response to their antidepressant.
This is a double-blind, placebo-controlled, 2-arm, parallel-group, Phase 2 study, randomized 1:1 (ABX-002: placebo).
The study will include the following stages:
1. Screening, approximately 35 days
2. 42-day Treatment Period
3. 2-week post do... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
06/17/2025
Locations: Autobahn Site #131, Birmingham, Alabama +41 locations
Conditions: Major Depressive Disorder
Clinical Validation of Samsung Smartwatch
Recruiting
Objective:
Wearable technology holds promising potential for mental health monitoring and detection. Samsung has developed an algorithm that they believe can detect signs of depression and anxiety in smartwatch users. They have used this algorithm to create a "Mindfulness Index," which is an easily understood visual index of mental health. The primary aim of the study is to evaluate the performance of Samsung's Mindfulness Index in identifying those who have received a diagnosis of Major Depres... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
06/16/2025
Locations: Center for Anxiety and Traumatic Stress Disorders, Massachusetts General Hospital, Boston, Massachusetts
Conditions: Major Depressive Disorder, Mood Disorders, Mental Health Issue
Invasive Decoding and Stimulation of Altered Reward Computations in Depression
Recruiting
Novel invasive neurostimulation stimulation strategies through neurosurgical interventions are emerging as a promising therapeutical strategy for major depressive disorder. These have been applied mostly to the anterior cingulate cortex, but other limbic brain regions have shown promise as anatomical targets for new neurostimulation strategies. The researchers seek to study neural activity in limbic brain areas implicated in decision behavior and mood regulation to identify novel targets for tre... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
06/11/2025
Locations: Icahn School of Medicine at Mount Sinai, New York, New York
Conditions: Major Depressive Disorder
Mindful Self-compassion for Anxiety and Depression: Impact of Delivery Method
Recruiting
The study will compare the delivery of an 8-week Mindful Self-Compassion training, in-person against video-conference, on anxiety and depression symptom severity in patients with diagnosed anxiety disorders (generalized anxiety disorder, social anxiety disorder, and panic disorder) or major depressive disorder or dysthymia.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
06/11/2025
Locations: Georgetown University Medical Center, Washington, District of Columbia
Conditions: Anxiety Disorders, Generalized Anxiety Disorder, Social Anxiety Disorder, Panic Disorder, Agoraphobia, Major Depressive Disorder, Persistent Depressive Disorder (Dysthymia)
1 - 12 of 125